N.L.. Why gene-therapy drugs are so expensive. The Economist 2016:1. [Ref.ID 100562]

Anónimo. Tacrolimus ointment (Protopic): reminder of a possible risk of malignancies including lymphomas and skin cancers. Drug Safety Update 2012;5:junio. [Ref.ID 92647]

Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Engl J Med 2009;360:518-21. [Ref.ID 85128]

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo M-G. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-58. [Ref.ID 85125]

Cole A. Child in gene therapy programme develops leukaemia. BMJ 2008;336:13. [Ref.ID 81950]

Gaspar HB, Parsley K L, Howe S, King D, Gilmour K, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Ghonaium AA, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-7. [Ref.ID 72191]

Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID in being confirmed. Lancet 2004;364:2155-6. [Ref.ID 72181]

Hescheler J, Welz A, Fleischmann BK. Searching for reputability: first randomised study on bone-marrow transplantation in the heart. Lancet 2004;364:121-2. [Ref.ID 70720]

Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schutz A, Landais P, Fisher A, for the European Group for Blood and Marrow Transplantation and the European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-60. [Ref.ID 65159]

Buckley RH. Treatment options for genetically determined immunodeficiency. Lancet 2003;361:541-2. [Ref.ID 65155]

Anónimo. FDA halts gene therapy trials. Scrip 2003;2817:19. [Ref.ID 64834]

Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-14. [Ref.ID 54339]

Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343:1313-24. [Ref.ID 53518]

Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000;60:249-71. [Ref.ID 52253]

Dobson R. Gene therapy saves immune deficient babies in France. BMJ 2000;320:1225. [Ref.ID 50755]

Matamoros Florí N, Milá Llambí J, Pons de Ves J. Imunodeficiencias primarias en España. Datos del Registro Español de Inmunodeficiencias Primarias. REDIP 1980-1999. Med Clin (Barc) 2000;114:96-100. [Ref.ID 49114]

Matamoros Florí N. Inmunodeficiencias primarias. Perspectivas actuales de diagnóstico y tratamiento. Med Clin (Barc) 2000;114:94-5. [Ref.ID 49113]

Fischer A. Thirty years of bone marrow transplantation for severe combined immunodeficiency. N Engl J Med 1999;340:559-61. [Ref.ID 42966]

Buckley RH, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts J L, Myers LA, Ward FE. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-16. [Ref.ID 42959]